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Summary box
 ► Health science research, funding and research ca-
pacity are insufficient to address Africa’s current 
unmet health needs, and there are ambitious coun-
try-set targets and frameworks for progress still to 
be met over the coming decade.
 ► There are substantial disparities in within-continent 
research and development (R&D) investment; esti-
mates from 2016 indicated South Africa, Egypt and 
Nigeria contributed almost two-thirds of the total do-
mestic spending on R&D in Africa.
 ► Measures of R&D outputs and capacity suggest 
both inter-regional and intraregional disparity based 
on investments, university rankings, number of re-
searchers, number of publications, patent holdings, 
clinical trial networks and pharmaceutical manufac-
turing capacity.
 ► Disparities in R&D capacity within Africa suggest 
the likely value of support for collaborative sci-
ence, technology and innovation networks between 
African nations, with any new partnerships harness-
ing the substantial momentum of R&D initiatives that 
already exist.
 ► Development of clear and context-relevant financing 
strategies and mechanisms can foster further public, 
private and international investment in R&D across 
the region.
AbSTrACT
Global research and development (R&D) pipelines for 
diseases that disproportionately affect African countries 
appear to be inadequate, with governments struggling 
to prioritise investment in R&D. This article provides 
insights into the sources of investment in health science 
research, available research capacity and level of 
research output in Africa. The African region comprises 
15% of the world’s population, yet only accounted for 
1.1% of global investments in R&D in 2016. There were 
substantial disparities within the continent, with Egypt, 
Nigeria and South Africa contributing 65.7% of the total 
R&D spending. In most countries of the Organisation for 
Economic Co-operation and Development, the largest 
source of R&D funding is the private sector. R&D in Africa 
is mainly funded by the public sector, with significant 
proportions of financing in many countries coming from 
international funding. Challenges that limit private sector 
investment include unstable political environments, poor 
governance and corruption. Evidence suggests various 
research output and research capacity limitations in Africa 
when considering a global context. Metrics that reflect 
this include university rankings, number of researchers, 
number of publications, clinical trials networks and 
pharmaceutical manufacturing capacity. Within the 
continent there are substantial regional disparities. 
Incentivising investment is crucial to foster current and 
future research output and research capacity. This paper 
outlines some of the many commendable initiatives 
under way. Innovative and collaborative financing 
mechanisms can stimulate further investment. Given the 
vast inequalities across Africa in R&D, strategies need to 
reflect the different capacities of countries to address this 
disparity.
InTroduCTIon
Africa produces about 2% of world research 
output, yet the region, as defined by the 
Unesco, accounts for 15% of the global popu-
lation and 25% of the global disease burden.1 
Research and development (R&D) pipelines 
for diseases that disproportionately affect 
African countries and address Africa’s unmet 
health needs are insufficient.2 More needs to 
be done. This includes leveraging investment 
and supporting capacities for health science 
research across Africa.
Many African countries have adopted targets 
that reflect aims of improved prosperity and 
achieving middle-income country status in 
the coming decade. Science, technology and 
innovation are key to these goals.3 As themes, 
they are central pillars to the African Union’s 
Science Technology and Innovation Strategy 
for Africa (STISA 2024) and Agenda 2063.4–6 
Infrastructure, financial and knowledge 
resources in African nations present a diverse 
set of challenges to investment in R&D.7 Yet 
rising gross domestic product (GDP) coupled 
with young, and growing, populations and 
increasing urbanisation in many countries 
may continue to drive growth in Africa and 
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Table 1 Levels of gross domestic expenditure in R&D (% 
of GDP)
Expenditure 
on R&D (% 
of GDP) Countries
>0.6 Egypt, Kenya, Malawi, Mali, Morocco, South 
Africa, Tunisia
0.4–0.6 Ethiopia, Gabon, Mozambique, Senegal, 
Tanzania, Uganda
0.2–0.4 Botswana, Ghana, Nigeria, Seychelles, Sudan, 
Togo, Zambia
0.1–0.2 Burkina Faso, Burundi, Gambia, Mauritius, 
Namibia
0<0.1 Algeria, Cabo Verde, Democratic Republic of the 
Congo, Lesotho, Madagascar
No data Angola, Benin, Cameroon, Central African 
Republic, Chad, Comoros, Congo, Cote d’Ivoire, 
Djibouti, Equatorial Guinea, Eritrea, Guinea, 
Guinea-Bissau, Liberia, Libya, Mauritania, Niger, 
Rwanda, Sao Tome and Principe, Sierra Leone, 
Somalia, South Sudan, Swaziland, Zimbabwe
Sources: refs13–15.
GDP, gross domestic product; R&D, research and development.
capacity for R&D growth.8 Health science research can 
play a central role in this.
This analysis offers an overview of funding and capaci-
ties for health science research and research capacity in 
Africa. It highlights challenges, opportunities and recom-
mendations for progress. Our analysis is informed by a 
semi-systematic literature review and expert interviews.
The literature review examined peer-reviewed and grey 
literature obtained using relevant search terms in online 
databases, with additional resources obtained through 
citations and institutional publication archives. Only 
English-language literature was reviewed, leaving scope 
for further review of evidence from French-speaking or 
Arabic-speaking authors. We undertook semi-structured 
interviews with nine representatives from governmental, 
non-governmental and academic institutions to enrich 
the scope of our research and engage further relevant 
literature (online supplementary appendix A for further 
information).9 Interviewees were selected using a judge-
ment sampling approach.10
SupporT for AfrICAn HeAlTH SCIenCe reSeArCH
r&d funding across Africa
In 2016, Africa accounted for 1.1% (US$22.3 billion) of 
global investments in R&D.11 Egypt, Nigeria and South 
Africa accounted for 65.7%, or US$14.66 billion, of Afri-
ca’s total R&D spending.11
In 2007 African Union countries committed to investing 
at least 1% of GDP in R&D. This recognised the impor-
tance of R&D to sustainable development and the need 
to address Africa’s health needs. This goal has remained 
unrealised. Across sub-Saharan Africa the average share 
of GDP devoted to R&D activities was only 0.4% in 2015, 
or the most recent available year.12 Countries closer to the 
1% target included Egypt, Kenya, Mali, Morocco, South 
Africa, and Tunisia while countries including Algeria, 
Cabo Verde and Lesotho invested less than 0.1% of GDP 
in R&D (online supplementary file A).13 R&D intensity 
is a sentinel indicator for economic policy. However, 
data on R&D investment are extremely limited for many 
African countries (see table 1).13–15
Sources of funding
The landscape of institutions funding African R&D is 
complex. Sources for domestic R&D include public 
sector, private sector and international funding. A 
country or region’s relative GDP devoted to R&D activi-
ties is known as gross expenditure on research and devel-
opment (GERD). R&D intensity is conventionally meas-
ured as the ratio of GERD to GDP. Most of the world’s 
largest developed economies have overall levels of R&D 
expenditure exceeding 2% of GDP. In Africa, almost all 
countries invest less than 1%.16
Although GDP per capita and GERD per capita have 
been rising in most African countries, levels are low by 
world standards, and there is a marked disparity within 
the continent.17 Public investments in strengthening 
research capacity require extensive capital resources. 
However, rates of return are often unpredictable, and it 
is difficult to prioritise spending versus pressing govern-
ment priorities in education, health and infrastructure. 
In most countries of the Organisation for Economic 
Co-operation and Development, the largest source 
of R&D funding is the private sector. African R&D has 
historically been mainly funded by the public sector, with 
international sources forming a substantial proportion 
of expenditures in many countries (see figure 1). For 
instance, foreign sources contributed significantly to 
2015 R&D expenditures in Ghana (31%), Senegal (41%) 
and Burkina Faso (60%).15 South Africa has been an 
exception, hosting substantial private sector support.17 
Encouraging governments to increase public funding 
of R&D and incentivising strong private sector engage-
ment in the funding and performance of R&D activities 
remain a key regional challenge.
Globally, pharmaceutical companies are among the top 
investors in R&D in the health science sector, but this is 
not the case in Africa. Few African companies have R&D 
units or R&D directors to oversee product development 
and technology transfer.3
CurrenT CApACITIeS
According to Unesco, Africa had an estimated 198 
researchers, in all fields, per million inhabitants in 
2014.13 This compares with 428 in Chile and more than 
4000 in the UK and the USA.13 Within Africa there is 
further disparity between countries. The top three coun-
tries with full-time researchers holding PhDs or equiva-
lent per million people were all in North Africa: Tunisia, 
Morocco and Egypt. An estimated 878 researchers per 
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Figure 1 Source of funding for gross expenditure on 
research and development by country. Source13: (Data from 
2014 or the latest available year).
million inhabitants in North Africa compares with 88 per 
million inhabitants in sub-Saharan Africa.13
Furthermore, many African researchers leave the conti-
nent. Over 10% of sub-Saharan Africans with graduate 
degrees emigrate. The numbers are even higher in the 
health workforce.17 Skilled researchers leave for several 
reasons. These can include a lack of local funding and 
training opportunities compared with high-income coun-
tries outside the region, which may have better research 
environments and working conditions. These reasons 
are common among regions experiencing a drain in 
research capacities.18
Retaining professionals with specific technical skills is 
essential to health research. However, other capacities 
are also essential to launch and sustain health research 
programmes. This involves training professionals to 
undertake administrative activities and hiring dedicated 
administrative staff. Key administrative activities for 
research include budget management, grant acquisition 
and procurement. Further dedicated support is essential 
for tasks involving human resource management, main-
tenance and legal support.18
There have been specific attempts to address emigra-
tion and harness the capacity of the African diaspora. 
The Africa Capacity Building Initiative, led by the 
Royal Society and UK Department for International 
Development (DFID), and the Carnegie African Dias-
pora Fellowship Program are two programmes guiding 
research expertise of African diaspora to the continent 
and helping to develop research and training capacities. 
The International Organization for Migration’s Migra-
tion for Development in Africa Diaspora Database and 
the Unesco-Hewlett Packard Brain Gain Initiative offer 
similar support.19–22 Further activities are outlined under 
the Initiatives and coalitions section of this paper.
Training more health science researchers in Africa
In 2016 the average tertiary enrolment rate in Africa, the 
percentage of high school graduates enrolling in univer-
sity, was 7.1%. The global average in 2016 was 25.1%.23 
However, the growth trend is positive, with returns on 
investment in higher education in Africa estimated at 
21%—the highest in the world.3 24 A 2015 report by the 
Africa-America Institute estimated that a 1-year increase 
in average tertiary education levels could raise annual 
GDP growth across Africa by 0.39%, potentially yielding 
an eventual increase in GDP of up to 12%.25
Sustainable health science research and research 
capacity building require strong scientific talent and 
high-quality universities. Only 26 universities in Africa 
featured in the Times Higher Education’s World Univer-
sity Rankings 2016–2017 (out of 980).26 Within the conti-
nent, the top 15 ranking universities span 7 countries (see 
table 2).26 One of the challenges that African universities 
face is the shortage of highly qualified researchers and 
other staff; a 2013 United Nations Economic Commission 
for Africa survey of nine African universities revealed that 
less than 50% of researchers and lecturers held PhDs.3
International initiatives have looked to address these 
issues. Examples include the World Bank establishment 
of the African Higher Education Centers of Excellence 
project, which aims to address regional development 
challenges and strengthen research capacity.27 Attracting 
foreign universities represents an opportunity for low-in-
come and middle-income countries to engage in inter-
national technology transfer and bolster learning. For 
example, in 2011, a new campus of Carnegie Mellon 
University launched in Rwanda with funding from the 
Rwandan Government and the African Development 
Bank.28
Collaboration across the region
In African countries researchers produce most publica-
tions with international coauthors, rather than with local 
coauthors. Most coauthors hail from institutions outside 
Africa. Nigeria and Egypt have been exceptions, with 
 o
n
 20 M
arch 2019 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2018-001047 on 4 March 2019. Downloaded from 
4 Simpkin V, et al. BMJ Glob Health 2019;4:e001047. doi:10.1136/bmjgh-2018-001047
BMJ Global Health
Table 2 Top 15 universities in Africa 2016–2017 (Times 
Higher Education Rankings)
Ranking University Country
1 University of Cape Town South Africa
2 University of Witwatersrand South Africa
3 Stellenbosch University South Africa
4 Makerere University Uganda
5 University of KwaZulu-Natal South Africa
6 University of Pretoria South Africa
7 University of Ghana Ghana
8 University of Nairobi Kenya
9 Suez Canal University Egypt
10 Alexandria University Egypt
11 Cairo University Egypt
12 University of Marrakech Cadi 
Ayyad
Morocco
13 University of South Africa South Africa
14 University of Ibadan Nigeria
15 Mohammed V University of 
Rabat
Morocco
Source: ref26.
Table 3 Cross-sector collaboration as a percentage (%) of total publications for sub-Saharan African regions and 
comparator institutions, 2003–2012
Region Academic–corporate (%) Academic–government (%)
Academic–medical 
(%)
East Africa 2.4 17.2 6.0
Southern Africa 2.4 17.4 7.5
West/Central Africa 1.0 10.5 4.2
South Africa 2.8 12.6 3.0
Source: ref30.
researchers producing most publications with domestic 
coauthors, 71% and 57%, respectively.29 See online 
supplementary file B for further details on this trend.
Africa’s regional research capacity has a fragmented 
appearance, with limited collaboration between subre-
gions. Inter-regional collaboration (without any South 
African or international collaborator) comprises 2% 
of all East African research, 0.9% of West and Central 
Africa, and 2.9% of Southern Africa (online supplemen-
tary file B).30 A 2009 study of the Southern African Devel-
opment Community (SADC) found only 5% of SADC 
papers published between 2005 and 2008 were coauthor-
ships between an SADC researcher and another African 
researcher.31
Collaborative academic networks tend to be driven 
by funding availability, which may have biased research 
towards collaborations with researchers outside Africa. 
The main collaborating institutions are in the USA, the 
UK and France, the countries that are also the largest 
funders of research in biosciences in Africa. There is 
an increasing trend towards collaboration on health 
research within Africa, particularly for malaria research. 
However, this is still much lower than collaboration with 
institutions in Europe and the USA.2 3
Cross-sector collaboration can foster knowledge 
transfer and alternative funding channels. Table 3 pres-
ents coauthored publications as a proxy for cross-sector 
collaboration, as a relative percentage of each region’s 
total output between 2003 and 2012.30 Across each region, 
academic–corporate collaboration accounts for only a 
small percentage of each region’s total output. Collab-
oration between the academic and corporate sector is 
mainly within health sciences and through collaborations 
with global pharmaceutical companies.30
Despite the potential value of international collab-
orative projects with high-income countries, there is 
justifiable concern. Priorities may not align. African insti-
tutions face challenges with leadership and ownership 
of research, which can create longer term issues with 
sustainability. In 2011, 38 African centres from across the 
continent were recognised as African Network for Drugs 
and Diagnostic Innovation (ANDI) Centres of Excel-
lence in health innovation. This will establish an alliance 
of African institutions with the expertise and resources 
to progress health innovation and to encourage intra-Af-
rican, South–South and North–South networking and 
collaboration.32 33
research outputs
Bibliometric indicators offer proxy measures, through 
the number of publications and citations, to assess 
the performance and influence of scientific research. 
Evidence suggests an estimated 60% growth in publica-
tions with African authors between 2008 and 2014.3 17 
However these research outputs appear to be unevenly 
distributed at the country and subregional levels.34 35
Publications alone, as an indicator of research output, 
may give an incomplete picture. It omits a significant level 
of production of non-academic research output. Surveys 
by the Health Research System Analysis Initiative indi-
cate that, despite low research production in sub-Saharan 
Africa, there is significant research activity, and institu-
tions make an effort to disseminate their research to the 
intended audience.36 Other important dissemination 
dimensions include publication in regional and national 
journals and editing working papers.36 Interviewees 
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noted that some African academics may publish research 
in local journals that are not indexed by the Institute for 
Scientific Information’s Web of Science. These journals 
may publish in a local language, as they target the local 
audience. Web of Science targets the international audi-
ence and is biased towards English-language content.
Countries in Europe and sub-Saharan Africa are part-
nering to increase research outputs through initiatives 
such as the European and Developing Countries Clin-
ical Trials Partnership (EDCTP). The EDCTP aims to 
alleviate the health and economic burden of infectious 
diseases in Africa, with a focus on phase II and III clin-
ical trials.37 The EDCTP focuses on multinational, multi-
centre projects. It has established regional networks for 
conducting clinical trials and promoting clinical research 
in sub-Saharan Africa. This promotes collaboration and 
sharing of expertise in resource-limited settings. Despite 
success stories, challenges remain. EDCTP projects 
receive limited contributions from African governments, 
with a heavy reliance on funding from Europe; this nega-
tively impacts African ownership of the research. There 
has also been difficulty transferring research funds to 
and between institutions in some cases.37
pharmaceutical r&d
The commercial sector is key to health science R&D. 
Thirty-seven African countries have some pharmaceu-
tical production, but few produce active pharmaceu-
tical ingredients and intermediates.38 These inequalities 
are replicated in the imbalance in global R&D outputs 
according to health needs. From 1975 to 2004, only 1.3% 
of the 1556 new chemical entities registered were meant 
for use in tropical diseases and tuberculosis, despite 
these diseases accounting for 12% of the global disease 
burden.39 A mix of regulatory and financial barriers to 
commercialisation, weak intellectual property rights and 
a lack of basic infrastructure disincentivise private sector 
investment.
Additionally, there are limited domestic capabilities 
to undertake the experimental development or transla-
tional research phase. Despite growing capacity for the 
third phase of clinical trials, the production and manu-
facturing phase of the value chain remains weak.3 Local 
production relies on imported active ingredients—
despite Africa’s raw material wealth. Interviewees noted 
that local manufacturing in Africa could foster afford-
ability of essential drugs, increase local job opportunities 
and reduce dependency on foreign support.
opporTunITIeS for progreSS
Available evidence suggests persistent low investment in 
health science research in Africa, with substantial gaps 
in research output and capacity compared with high-in-
come countries and some emerging economies. Several 
initiatives seek to create opportunities and address 
barriers towards progress.
Key challenges to catalysing investment include a lack 
of ownership of research agendas, poor capacity reten-
tion and inadequate knowledge.40 Institutional weak-
nesses also lead to difficulties in catalysing research. 
These include corruption, governance issues and polit-
ical instability. A 2015 Transparency International survey 
found 22% of Africans who encountered a public service 
in the past 12 months say they paid a bribe.41 Assessing 
governance capacity also offers important structure to 
considering methods to increase public and private 
sector investment in health science R&D. The Ibrahim 
Index, an independent index for governance quality in 
Africa, notes most countries show signs of an improved 
overall governance score over the past decade. However, 
over half of the 40 index countries have shown signs of 
slackening and even reversals in their progress.42
Several challenges limit private sector investment. 
These include unstable political environments, poor 
governance, weak regulatory structures and corruption. 
Public policies may exacerbate market weaknesses, such 
as the imposition of taxes and price controls on essential 
medicines and weak or absent intellectual property laws 
and regulatory frameworks. Enabling public policies that 
create adequate health sector infrastructure, including 
medical facilities, diagnostic systems and medical service 
delivery systems, is also key to attracting private sector 
investment.43
As African pharmaceutical manufacturers increasingly 
develop their own products, there is also an increased 
need for local regulatory expertise, and this needs to 
be developed to attract businesses.3 New institutions 
can develop with guidance from established regulatory 
bodies, such as the Food and Drugs Board in Ghana.44
External and international funding remains critical to 
the sustainability of research and innovation systems in 
many African countries. However, there are cases where 
sub-Saharan African health ministries have been over-
whelmed with donor requests to fund research activities, 
while neighbouring countries, with equally substantive 
disease burdens, have a paucity of funding.45
Initiatives and coalitions
This paper highlights a selection of the many commend-
able initiatives that target improved research capacity in 
Africa. Effective stimulation of investment, in such activ-
ities, is critical to address many of the issues outlined 
above and to improve research capacity.
Traditional incentives for investment in product devel-
opment often rely on having an environment with a 
well-established infrastructure. For countries with no 
significant research capacity, the priority needs to be 
on developing infrastructure and education, oriented 
towards long-term achievements, to train the researchers 
of tomorrow. For countries with some research capacity 
already in place, investment should focus on further 
developing centres of excellence, as is the focus of the 
World Bank African Higher Education Centers of Excel-
lence project.
 o
n
 20 M
arch 2019 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2018-001047 on 4 March 2019. Downloaded from 
6 Simpkin V, et al. BMJ Glob Health 2019;4:e001047. doi:10.1136/bmjgh-2018-001047
BMJ Global Health
Figure 2 Research programmes funded by organisations 
in Africa in 2015. Source.24 Organisations listed in figure: 
BMGF, Bill & Melinda Gates Foundation; CIHR, Canadian 
Institutes of Health Research; EDCTP, European and 
Developing Countries Clinical Trials Partnership; EU, 
European Union; MRC, UK Medical Research Council; NIH, 
US National Institutes of Health; SIDA, Swedish International 
Development Cooperation Agency; SRC, Swedish Research 
Council; Wellcome Trust.
International partners can also risk engaging in a 
manner that hinders capacity development, despite 
best intentions. This is a problem for local and inter-
national donors, academic institutions and non-govern-
mental organisations. Partnerships can be imbalanced 
and inequitable, favouring the careers and priorities of 
researchers based outside of Africa.46 Power imbalances 
require specific interventions to address them, such as 
having core principles to guide research partnerships. 
These include the work of the Canadian Coalition for 
Global Health Research, Commission for Research Part-
nerships with Developing Countries (KFPE) and the 
Research Fairness Initiative.47
African-led solutions can address such imbalances 
and weaknesses in infrastructure. The ANDI was estab-
lished in 2008 as a pan-African agency with a mission to 
promote and sustain African-led health innovation to 
address the health needs of the poor, and has contrib-
uted significantly to the innovation space in Africa.34 48 In 
2015, the Alliance for Accelerating Excellence in Africa 
(AESA) was created by the African Academy of Sciences 
(AAS) and the New Partnership for Africa’s Development 
(NEPAD) Agency, with the support of DFID, the Well-
come Trust and the Bill & Melinda Gates Foundation. 
The AESA is a vehicle to manage research funding and 
provide research leadership for the continent of Africa, 
supporting the training of scientists and driving Africa’s 
research agenda. The ‘Coalition for Research and Inno-
vation’ (CARI) is another platform within Africa from 
which a coalition of African leaders, African philan-
thropists and international funders can build a highly 
coordinated, well-funded and innovative African R&D 
community. The Biosciences Eastern and Central Africa 
is a further NEPAD-African Union initiative convening 
scientists from the two regions to work on common chal-
lenges in food and nutritional security.49 The AAS 2018 
report on ‘Africa Beyond 2030’49 outlines the current 
landscape of such initiatives across the region.49
Such initiatives extend to suggestions for coordinating 
pooled funding initiatives for African R&D. These include 
a pan-African fund with contributions from governments, 
donors and the private sector.5 Such mechanisms need 
ethical governance frameworks representative of local 
priorities and that prevent countries receiving dispropor-
tionate amounts of support compared with their neigh-
bours. A better understanding of how existing investments 
work can also support more effective funding. World 
RePORT is one way to do so, as an online database that 
maps research projects funded around the world. World 
RePORT provides information on investments and part-
nerships from some of the largest biomedical research 
funders.24 Figure 2 illustrates the percentage of research 
programmes within Africa funded by the global research 
funders who provided data.
ConCluSIon
Science, technology and innovation are key to Africa’s 
future. Most experience on life science research policy 
development, however, comes from high-income coun-
tries in Europe and North America where many elements 
of infrastructure are already in place.50 Clear develop-
ment strategies and innovative financing mechanisms 
could encourage public, private and international invest-
ment. For this to be sustainable, incentives need to be 
relevant to the settings where they are used.51
Many initiatives are already in place in Africa, and 
momentum should build behind these to support R&D 
capacity building. Doing so requires a collaborative 
approach that ensures African leadership and owner-
ship. Initiatives such as CARI and AESA are Africa-led, 
Africa-centred and Africa-specific platforms for collabo-
ration. With domestic and international support, these 
and other initiatives can address development challenges 
in Africa and foster long-term sustainable development 
of excellence and leadership in science, research and 
innovation.
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